ArticleBMC medicine2025
Cardiovascular risk burden and guideline-recommended lipid and blood pressure goals in an Italian Cohort: findings from the HUMTELEMED web-based platform.
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough the 2021 European Society of Cardiology (ESC) guidelines and Systematic COronary Risk Estimation 2 (SCORE2) models provide structured risk assessment, their complexity may hinder routine use. The web-based platform HUMTELEMED was developed to integrate cardiovascular risk (CVR) stratification and therapeutic targets in a user-friendly interface. We evaluated CVR distribution, the proportion of patients meeting LDL-cholesterol (LDL-C) and blood pressure (BP) goals, and the use of lipid- and BP-lowering therapies in a large Italian cohort.
methodsThis cross-sectional study included 7260 anonymised adults aged ≥ 40 years who accessed the platform between December 2022 and September 2024. Most were in primary prevention, without established CV disease (99.5%, n = 7224). CVR was stratified using SCORE2, SCORE2-Older People (OP), and 2021 ESC charts. Proportions of patients meeting guideline-based LDL-C and BP goals were also assessed overall and in subgroups.
resultsMean age was 59.4 ± 11.8 years; 55.3% (n = 4046) were male, 46.5% (n = 3373) had hypertension, 18.3% (n = 1298) obesity, 8.5% (n = 617) diabetes, 11.8% (n = 860) chronic kidney disease, 16.0% (n = 1165) peripheral artery disease, and 37.2% (n = 2705) reported smoking. CVR distribution was 21.9% (n = 1593) low-to-moderate, 38.1% (n = 2764) high, and 40.0% (n = 2903) very high/extreme. LDL-C goals were met by only 11.3% (n = 819) overall and 15.9% (n = 342) of those on LLT. BP goals were met by 75.6% (n = 5492) overall, and by 68.3% (n = 2304) of patients on antihypertensive therapy. Goal meeting declined with increasing CVR: LDL-C, 44.8% low-to-moderate vs. 13.8% high vs. 11.6% very high/extreme (p < 0.001); BP, 89.5% vs. 78.6% vs. 65.4% (p < 0.001). Subgroup analyses showed lower proportions meeting LDL-C and BP goals in men (10.6% vs. 12.0% and 73.1% vs. 78.7%, respectively; p < 0.001), older adults (10.6% vs. 11.4% and 70.8% vs. 76.9%, respectively; p < 0.001), and individuals with obesity (9.0% vs. 13.8% and 63.0% vs. 83.1%, respectively; p < 0.001).
conclusionsIn this large real-world Italian cohort, the proportion of patients meeting LDL-C and BP goals was critically low, particularly among those at the highest CVR, despite pharmacological treatment. These findings highlight the urgent need for improved implementation of guideline-based prevention strategies, including greater use of combination therapies, better risk communication, and stronger adherence to ESC recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.